WebIn 2024, Atara and Pierre Fabre entered a strategic collaboration to commercialize tabelecleucel (tab-cel ® )* in Europe, Middle East, Africa, and other select emerging markets for Epstein-Barr virus (EBV) positive cancers. Atara retained full rights to tab-cel ® in other major markets, including North America, Asia Pacific, and Latin America. WebJun 4, 2024 · SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its …
A Study to Evaluate Tabelecleucel in Participants With …
WebJan 10, 2024 · Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post ... WebJun 7, 2024 · Atara is applying this one platform to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV + PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next ... l-4959 bascharage
Atara Biotherapeutics Announces Positive Results from Pivotal …
WebTab-cel®, Atara's most advanced T-cell immunotherapy in development, is a potential treatment for patients with Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+ PTLD), as well as other EBV associated … WebDec 14, 2024 · Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post ... Web© 2024 Atara Biotherapeutics, Inc. All rights reserved. progressive stocks with dividends